Search Results - "ROCKSTROH, Jurgen K"

The path to hepatitis C elimination: who are we leaving behind and why? by Rockstroh, Jurgen K., Swan, Tracy, Chang, Judy, Elamouri, Fauzi, Lloyd, Andrew R.

“…The 2016 World Health Organization (WHO) 2030 global elimination targets for hepatitis C virus (HCV) are: 80% of those with chronic HCV treated, 90% reduction…”
Get full text

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials by Eron, Joseph J, Prof, Cooper, David A, Prof, Steigbigel, Roy T, Prof, Clotet, Bonaventura, MD, Gatell, Jose M, Prof, Kumar, Princy N, Prof, Rockstroh, Jurgen K, Prof, Schechter, Mauro, Prof, Markowitz, Martin, Prof, Yeni, Patrick, MD, Loutfy, Mona R, MD, Lazzarin, Adriano, Prof, Lennox, Jeffrey L, Prof, Strohmaier, Kim M, BS, Wan, Hong, MS, Barnard, Richard JO, PhD, Nguyen, Bach-Yen T, MD, Teppler, Hedy, MD

“…Summary Background Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase…”
Get full text

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials by Steigbigel, Roy T., Cooper, David A., Teppler, Hedy, Eron, Joseph J., Gatell, Jose M., Kumar, Princy N., Rockstroh, Jurgen K., Schechter, Mauro, Katlama, Christine, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R., Lazzarin, Adriano, Lennox, Jeffrey L., Clotet, Bonaventura, Zhao, Jing, Wan, Hong, Rhodes, Rand R., Strohmaier, Kim M., Barnard, Richard J., Isaacs, Robin D., Nguyen, Bach-Yen T.

“…BENCHMRK-1 and -2 are ongoing double-blind phase III studies of raltegravir in patients experiencing failure of antiretroviral therapy with triple-class…”
Get full text

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials by Sax, Paul E, Erlandson, Kristine M, Lake, Jordan E, Mccomsey, Grace A, Orkin, Chloe, Esser, Stefan, Brown, Todd T, Rockstroh, Jürgen K, Wei, Xuelian, Carter, Christoph C, Zhong, Lijie, Brainard, Diana M, Melbourne, Kathleen, Das, Moupali, Stellbrink, Hans-Jürgen, Post, Frank A, Waters, Laura, Koethe, John R

“…Abstract Background Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate…”
Get full text

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus by Sax, Paul E, Rockstroh, Jürgen K, Luetkemeyer, Anne F, Yazdanpanah, Yazdan, Ward, Douglas, Trottier, Benoit, Rieger, Armin, Liu, Hui, Acosta, Rima, Collins, Sean E, Brainard, Diana M, Martin, Hal

“…Abstract Background Bictegravir (B)/emtricitabine (F)/tenofovir alafenamide (TAF) is guideline-recommended treatment for human immunodeficiency virus type 1…”
Get full text

Elimination of HCV as a public health concern among people who inject drugs by 2030 – What will it take to get there? by Grebely, Jason, Dore, Gregory J., Morin, Sébastien, Rockstroh, Jürgen K., Klein, Marina B.

“…Introduction: Globally, there is a considerable burden of HCV and HIV infections among people who inject drugs (PWID) and transmission of both infections…”
Get full text

The way forward in HCV treatment - finding the right path by Manns, Michael P, Foster, Graham R, Rockstroh, Jürgen K, Zeuzem, Stefan, Zoulim, Fabien, Houghton, Michael

“…Infection with the hepatitis C virus (HCV) represents an important health-care problem worldwide. The prevalence of HCV-related disease is increasing, and no…”
Get full text

Human Immunodeficiency Virus (HIV) Care Models During the Coronavirus Disease 2019 (COVID-19) Era by Guaraldi, Giovanni, Milic, Jovana, Martinez, Esteban, Kamarulzaman, Adeeba, Mussini, Cristina, Waters, Laura, Pozniak, Anton, Mallon, Patrick, Rockstroh, Jürgen K, Lazarus, Jeffrey V

“…Abstract The coronavirus disease 2019 (COVID-19) pandemic is an unprecedented global challenge that substantially risks reversing the progress in ending human…”
Get full text

Late HIV diagnosis: Where we stand and the way forward by Parczewski, Miłosz, Rockstroh, Jürgen K.

Get full text

Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity Against SARS-CoV-2 After Natural Infection Is More Potent Than After Vaccination by Rieke, Gereon J, van Bremen, Kathrin, Bischoff, Jenny, ToVinh, Michael, Monin, Malte B, Schlabe, Stefan, Raabe, Jan, Kaiser, Kim M, Finnemann, Claudia, Odainic, Alexandru, Kudaliyanage, Anushka, Latz, Eicke, Strassburg, Christian P, Boesecke, Christoph, Schmidt, Susanne V, Krämer, Benjamin, Rockstroh, Jürgen K, Nattermann, Jacob

“…Abstract We compared the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike-specific antibodies to induce natural killer…”
Get full text

Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy by Krämer, Benjamin, Goeser, Felix, Lutz, Philipp, Glässner, Andreas, Boesecke, Christoph, Schwarze-Zander, Carolynne, Kaczmarek, Dominik, Nischalke, Hans Dieter, Branchi, Vittorio, Manekeller, Steffen, Hüneburg, Robert, van Bremen, Tobias, Weismüller, Tobias, Strassburg, Christian P, Rockstroh, Jürgen K, Spengler, Ulrich, Nattermann, Jacob

“…Innate lymphocyte cells (ILCs), a novel family of innate immune cells are considered to function as key orchestrators of immune defences at mucosal surfaces…”
Get full text

Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART) by Bischoff, Jenny, Gu, Wenyi, Schwarze-Zander, Carolynne, Boesecke, Christoph, Wasmuth, Jan-Christian, van Bremen, Kathrin, Dold, Leona, Rockstroh, Jürgen K, Trebicka, Jonel

“…De novo steatosis is the main criteria for non-alcoholic fatty liver disease (NAFLD), which is becoming a clinically relevant comorbidity in HIV-infected…”
Get full text

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial by DeJesus, Edwin, Rockstroh, Jürgen K, MD, Henry, Keith, MD, Molina, Jean-Michel, MD, Gathe, Joseph, MD, Ramanathan, Srinivasan, PhD, Wei, Xuelian, PhD, Yale, Kitty, MSc, Szwarcberg, Javier, MD, White, Kirsten, Prof, Cheng, Andrew K, MD, Kearney, Brian P, Prof

“…Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),…”
Get full text

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection by Steigbigel, Roy T, Cooper, David A, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R, Lennox, Jeffrey L, Gatell, Jose M, Rockstroh, Jurgen K, Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Zhao, Jing, Chen, Joshua, Ryan, Desmond M, Rhodes, Rand R, Killar, John A, Gilde, Lucinda R, Strohmaier, Kim M, Meibohm, Anne R, Miller, Michael D, Hazuda, Daria J, Nessly, Michael L, DiNubile, Mark J, Isaacs, Robin D, Nguyen, Bach-Yen, Teppler, Hedy

“…For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that…”
Get full text

Late presentation of chronic viral hepatitis for medical care: a consensus definition by Mauss, Stefan, Pol, Stanislas, Buti, Maria, Duffell, Erika, Gore, Charles, Lazarus, Jeffrey V, der Grient, Hilje Logtenberg-van, Lundgren, Jens, Mozalevskis, Antons, Raben, Dorthe, Schatz, Eberhard, Wiktor, Stefan, Rockstroh, Jürgen K

“…We present two consensus definitions of advanced and late stage liver disease being used as epidemiological tools. These definitions can be applied to assess…”
Get full text

Impact of Hepatitis C cure on risk of mortality and morbidity in people with HIV after ART initiation by Chalouni, Mathieu, Trickey, Adam, Ingle, Suzanne M., Sepuvelda, Maria Antonia, Gonzalez, Juan, Rauch, Andri, Crane, Heidi M., Gill, M John, Rebeiro, Peter F., Rockstroh, Jürgen K., Franco, Ricardo A., Touloumi, Giota, Neau, Didier, Laguno, Montserrat, Rappold, Michaela, Smit, Colette, Sterne, Jonathan AC, Wittkop, Linda

“…OBJECTIVE: Hepatitis C Virus (HCV) co-infection is associated with increased morbidity and mortality in people with HIV (PWH). Sustained virological response…”
Get full text

Implementation of EACS vaccination recommendations among people living with HIV by Breitschwerdt, Sven, Schwarze-Zander, Carolynne, Al Tayy, Ahmad, Mutevelli, Julia, Wasmuth, Jan-Christian, Rockstroh, Jürgen K., Boesecke, Christoph

“…Objectives With modern combination antiretroviral Treatment (cART) a normal life expectancy among people living with HIV (PLWH) has become reality if started…”
Get full text

Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study by Molina, Jean-Michel, Prof, Orkin, Chloe, MD, Iser, David M, MBBS, Zamora, Francisco-Xavier, MD, Nelson, Mark, MBBS, Stephan, Christoph, Prof, Massetto, Benedetta, MD, Gaggar, Anuj, MD, Ni, Liyun, MA, Svarovskaia, Evguenia, PhD, Brainard, Diana, MD, Subramanian, G Mani, MD, McHutchison, John G, MD, Puoti, Massimo, Prof, Rockstroh, Jürgen K, Prof

“…Summary Background Although interferon-free regimens are approved for patients co-infected with HIV and genotype-2 or genotype-3 hepatitis C virus (HCV),…”
Get full text

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection by Cooper, David A, Steigbigel, Roy T, Gatell, Jose M, Rockstroh, Jurgen K, Katlama, Christine, Yeni, Patrick, Lazzarin, Adriano, Clotet, Bonaventura, Kumar, Princy N, Eron, Joseph E, Schechter, Mauro, Markowitz, Martin, Loutfy, Mona R, Lennox, Jeffrey L, Zhao, Jing, Chen, Joshua, Ryan, Desmond M, Rhodes, Rand R, Killar, John A, Gilde, Lucinda R, Strohmaier, Kim M, Meibohm, Anne R, Miller, Michael D, Hazuda, Daria J, Nessly, Michael L, DiNubile, Mark J, Isaacs, Robin D, Teppler, Hedy, Nguyen, Bach-Yen

“…In subgroups of two phase 3 studies, patients with high-risk features for failure of antiretroviral therapy, such as a low CD4 count, high base-line level of…”
Get full text

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial by van Lunzen, Jan, Prof, Maggiolo, Franco, MD, Arribas, José R, Prof, Rakhmanova, Aza, MD, Yeni, Patrick, Prof, Young, Benjamin, MD, Rockstroh, Jürgen K, Prof, Almond, Steve, MMath, Song, Ivy, PhD, Brothers, Cindy, MSPH, Min, Sherene, MD

“…Summary Background Dolutegravir (S/GSK1349572) is a new HIV-1 integrase inhibitor that has antiviral activity with once daily, unboosted dosing. SPRING-1 is an…”
Get full text